METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Clinical trials for METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug targets tough prostate cancer
Disease control Recruiting nowThis study tests a radioactive drug called lutetium Lu 177 dotatate in men with advanced prostate cancer that has neuroendocrine features. The drug seeks out and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors. About 35…
Matched conditions: METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New scan could spot prostate cancer that hides from standard tests
Diagnosis Recruiting nowThis early study tests whether a special PET scan using 18F-fluciclovine can find prostate cancer that doesn't show up well on standard PSMA scans. The study will include 30 men with advanced prostate cancer that either has low PSMA levels or has changed into a more aggressive ne…
Matched conditions: METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC